Dr. Patrick E. Whitten, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Southern Illinois University School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,359
Licensed in Illinois since 1992, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Southern Illinois University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
IL license 036084941 (first issued 1992; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Medical Center Peoria, IL
- Osf Saint Elizabeth MDl Ctr Peru, IL
- St Joseph Medical Center Bloomington, IL
- Saint James Hospital Pontiac, IL
Medical groups
- Osf Multi-Specialty Group (2,114 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,359
- Services billed
- 3,042
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 913 | 732 |
| Test to examine how well the lungs exchange gases | 286 | 278 |
| Test to determine lung volumes using sensors | 285 | 277 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 269 | 259 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 184 | 99 |
| Test for exercise-induced lung stress | 149 | 134 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 118 | 109 |
| Aspiration of initial secretion of lung airway using an endoscope | 112 | 103 |
| New patient office or other outpatient visit, 60-74 minutes | 81 | 81 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 71 | 69 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Peoria, IL | 1,031 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Peoria, IL | 686 |
| Azithromycin Other prescribers in Peoria, IL | 408 |
| Prednisone Other prescribers in Peoria, IL | 406 |
| Montelukast Sodium Other prescribers in Peoria, IL | 324 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Peoria, IL | 222 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Peoria, IL | 161 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Peoria, IL | 144 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Peoria, IL | 144 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Peoria, IL | 139 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $64.12 in total to this clinician.
| Pulmonx Corporation | $64.12 |
|---|
| Food and Beverage | $64.12 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $307,959 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Alkermes, Inc. · Completed · NCT06555783 - A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. · Recruiting · NCT06767683 - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Alkermes, Inc. · Completed · NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590 - CS006 RHEOX PIVOTAL
Galvanize Therapeutics, Inc - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.